Modeled impact of the COVID-19 pandemic and associated reduction in adult vaccinations on herpes zoster in the United States

References

• Centers for Disease Control and Prevention (CDC). Epidemiology and prevention of vaccine-preventable diseases: herpes zoster; 2020a [accessed 2021 Aug 17]. https://www.cdc.gov/vaccines/pubs/pinkbook/herpes-zoster.html .
   Google Scholar
• Centers for Disease Control and Prevention (CDC). Shingles (herpes zoster); 2019 [accessed 2021 Aug 17]. https://www.cdc.gov/shingles/about/index.html .
   Google Scholar
• Singhal PK, Makin C, Pellissier J, Sy L, White R, Saddier P. Work and productivity loss related to herpes zoster. J Med Econ. 2011;14 (5):639–5. doi:10.3111/13696998.2011.607482.
   PubMedGoogle Scholar
• Schmader KE, Sloane R, Pieper C, Coplan PM, Nikas A, Saddier P, Chan ISF, Choo P, Levin MJ, Johnson G, et al. The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. Clin J Pain. 2007;23(6):490–96. doi:10.1097/AJP.0b013e318065b6c9.
   PubMed Web of Science ®Google Scholar
• Dooling KL, Guo A, Patel M, Lee GM, Moore K, Belongia EA, Harpaz R. Recommendations of the advisory committee on immunization practices for use of herpes zoster vaccines. Morb Mortal Wkly Rep. 2018;67(3):103–08. doi:10.15585/mmwr.mm6703a5.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Advisory committee on immunization practices (ACIP); 2021 [accessed 2021 Dec 10]. https://www.cdc.gov/vaccines/acip/recommendations.html .
   Google Scholar
• Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang S-J, Levin MJ, McElhaney JE, Poder A, Puig-Barberà J, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372:2087–96. doi:10.1056/NEJMoa1501184.
   PubMed Web of Science ®Google Scholar
• Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang S-J, Díez-Domingo J, Godeaux O, Levin MJ, McElhaney JE, Puig-Barberà J, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375:1019–32. doi:10.1056/NEJMoa1603800.
   PubMed Web of Science ®Google Scholar
• Curran D, Kim JH, Matthews S, Dessart C, Levin MJ, Oostvogels L, Riley ME, Schmader KE, Cunningham AL, McNeil SA, et al. Recombinant zoster vaccine is efficacious and safe in frail individuals. J Am Geriatr Soc. 2021;69(3):744–52. doi:10.1111/jgs.16917.
   PubMed Web of Science ®Google Scholar
• Curran D, Oostvogels L, Heineman T, Matthews S, McElhaney J, McNeil S, Diez-Domingo J, Lal H, Andrews C, Athan E, et al. Quality of life impact of an adjuvanted recombinant zoster vaccine in adults aged 50 years and older. J Gerontol A Biol Sci Med Sci. 2019;74(8):1231–38. doi:10.1093/gerona/gly150.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Vaccines and preventable diseases: frequently asked questions about Shingrix; 2020b [accessed 2021 Aug 17]. https://www.cdc.gov/vaccines/vpd/shingles/hcp/shingrix/faqs.html .
   Google Scholar
• Curran D, Patterson B, Varghese L, Van Oorschot D, Buck P, Carrico J, Hicks K, Lee B, Yawn B. Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States. Vaccine. 2018;36(33):5037–45. doi:10.1016/j.vaccine.2018.07.005.
   PubMed Web of Science ®Google Scholar
• Boutry C, Hastie A, Shi M, Diez-Domingo J, Tinoco JC, Yu C-J, Pirrotta, P, Kalema, G, Schuind, A . 8. The adjuvanted recombinant zoster vaccine (RZV) confers long-term protection against herpes zoster: interim results of an extension study (ZOSTER-049) of Two Clinical Trials (ZOE-50 and ZOE-70). Open Forum Infect Dis. 2020;7:S4–S5 doi:10.1093/ofid/ofaa417.007.
   Google Scholar
• Boutry C, Hastie A, Diez-Domingo J, Tinoco JC, Yu C-J, Andrews C, Beytout J, Caso C, Cheng H-S, Cheong HJ, et al. The adjuvanted recombinant zoster vaccine confers long-term protection against herpes zoster: interim results of an extension study of the pivotal phase III clinical trials (ZOE-50 and ZOE-70). Clin Infect Dis. 2021. doi:10.1093/cid/ciab629.
   Web of Science ®Google Scholar
• Patterson BJ, Chen C-C, McGuiness CB, Glasser LI, Sun K, Buck PO. Early examination of real-world uptake and second-dose completion of recombinant zoster vaccine in the United States from October 2017 to September 2019. Hum Vaccines Immunother. 2021;17(8):2482–87 doi:10.1080/21645515.2021.1879579.
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline Biologicals: SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted), suspension for intramuscular injection; 2017 [accessed 2021 Aug 26]. https://www.fda.gov/media/108597/download.
   Google Scholar
• Hong K, Zhou F, Tsai Y, Jatlaoui TC, Acosta AM, Dooling KL, Kobayashi M, Lindley MC. Decline in receipt of vaccines by medicare beneficiaries during the COVID-19 pandemic—United States, 2020. Morb Mortal Wkly Rep. 2021;70(7):245–49. doi:10.15585/mmwr.mm7007a4.
   PubMed Web of Science ®Google Scholar
• Brooks HE, McLendon LA, Daniel CL. The impact of COVID-19 on pediatric vaccination rates in Alabama. Prev Med Rep. 2021;22:101320. doi:10.1016/j.pmedr.2021.101320.
   PubMedGoogle Scholar
• Murthy BP, Zell E, Kirtland K, Jones-Jack N, Harris L, Sprague C, Schultz J, Le Q, Bramer CA, Kuramoto S, et al. Impact of the COVID-19 pandemic on administration of selected routine childhood and adolescent vaccinations—10 US Jurisdictions, March–September 2020. Morb Mortal Wkly Rep. 2021;70(23):840–45. doi:10.15585/mmwr.mm7023a2.
   PubMed Web of Science ®Google Scholar
• Wang B, Guo S, Yao Y, Li Y, Zhang G. Dermatologists may need to pay more attention to herpes zoster during the pandemic of COVID-19. Infect Dis. 2020;52(12):917–18. doi:10.1080/23744235.2020.1797158.
   PubMed Web of Science ®Google Scholar
• Katz J, Yue S, Xue W. Herpes simplex and herpes zoster viruses in COVID-19 patients. Ir J Med Sci. 2021;1–5.
   Web of Science ®Google Scholar
• Maia CMF, Marques NP, de Lucena EHG, de Rezende LF, Martelli DRB, Martelli-Júnior H. Increased number of herpes zoster cases in Brazil related to the COVID-19 pandemic. Int J Infect Dis. 2021;104:732–33. doi:10.1016/j.ijid.2021.02.033.
   PubMed Web of Science ®Google Scholar
• Choi HG, Kim E-J, Lee YK, Kim M. The risk of herpes zoster virus infection in patients with depression: a longitudinal follow-up study using a national sample cohort. Medicine. 2019;98(40): e17430.
   PubMed Web of Science ®Google Scholar
• Marra F, Parhar K, Huang B, Vadlamudi N. Risk factors for herpes zoster infection: a meta-analysis. Open Forum Infect Dis. 7(1): 2020, ofaa005 doi:10.1093/ofid/ofaa005.
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Hartstein G, Rosner HL, Walther RR, Sweeney EW, Brand L. A high-risk method for studying psychosocial antecedents of chronic pain: the prospective investigation of herpes zoster. J Abnorm Psychol. 1992;101(1):200–05. doi:10.1037/0021-843X.101.1.200.
   PubMed Web of Science ®Google Scholar
• Curran D, Schmidt-Ott R, Schutter U, Simon J, Anastassopoulou A, Matthews S. Impact of herpes zoster and postherpetic neuralgia on the quality of life of Germans aged 50 or above. BMC Infect Dis. 2018;18(1):496. doi:10.1186/s12879-018-3395-z.
   PubMedGoogle Scholar
• Diez-Domingo J, Parikh R, Bhavsar AB, Cisneros E, McCormick N, Lecrenier N. Can COVID-19 increase the risk of herpes zoster? A narrative review. Dermatol Ther (Heidelb.) 2021;11(4):1119–26.
   PubMed Web of Science ®Google Scholar
• Yu X, Li L, Chan MTV, Wu WKK. Bioinformatic analyses suggest augmented interleukin-17 signaling as the mechanism of COVID-19-associated herpes zoster. Environ Sci Pollut Res. 2021; doi:10.1007/s11356-021-15567-x.
   Web of Science ®Google Scholar